Clorox (NYSE: CLX) details FY26 results, GOJO deal and FY27 EPS view

Q: What were Clorox (CLX) net sales and EPS for fiscal 2026?

Clorox reported fiscal 2026 net sales of $6.72 billion , down 5% year over year, and diluted EPS of $4.81 , a 26% decrease from $6.52. Adjusted EPS fell 28% to $5.53 from $7.72.

Q: How did Clorox (CLX) perform in Q4 fiscal 2026?

In Q4 fiscal 2026, Clorox’s net sales decreased 2% to $1.95 billion , with organic sales down 13%. Diluted EPS declined 50% to $1.34 , and adjusted EPS dropped 42% to $1.66 as gross margin fell to 41.3%.

Q: What impact did the GOJO acquisition and ERP transition have on Clorox (CLX)?

The GOJO acquisition added about 3 points to fiscal 2026 net sales and about 10 points to Q4 sales growth but pressured gross margin via inventory step-up costs. ERP-related shipment timing reduced fiscal 2026 organic sales by about 7.5 points and EPS by roughly $0.90 .

Q: What is Clorox (CLX) guiding for fiscal 2027 sales and EPS?

For fiscal 2027, Clorox expects net sales to rise 13%–14% , including about 9.5 points from GOJO, and organic sales to grow about 3.5%–4.5%. Diluted EPS is projected at $5.41–$5.71 and adjusted EPS at $5.70–$6.00 .

Q: How did Clorox (CLX) cash flow and free cash flow look in fiscal 2026?

Net cash provided by operations was $612 million , down from $981 million, mainly due to the Glad venture-termination payment. Adjusted free cash flow was $881 (dollars in millions), representing 13.1% of net sales versus 10.7% in fiscal 2025.

Q: What shape is Clorox’s (CLX) balance sheet in after fiscal 2026?

At June 30, 2026, Clorox had total assets of $7.79 billion and total liabilities of $7.54 billion , including $3.98 billion of long-term debt and $1.09 billion of notes and loans payable, with total stockholders’ equity of $252 million.

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

The Clorox Company reported fourth-quarter and fiscal 2026 results marked by lower sales and earnings while integrating its GOJO acquisition and completing a major U.S. ERP transition. Q4 net sales decreased 2% to $1.95 billion, with organic sales down 13% as the company lapped elevated shipments ahead of last year’s ERP cutover. Q4 diluted EPS fell 50% to $1.34 and adjusted EPS declined 42% to $1.66, reflecting lower volume, a 520-basis-point gross-margin decline to 41.3%, and GOJO-related inventory step-up and integration costs.

For fiscal 2026, net sales declined 5% to $6.72 billion and organic sales fell 8%. Diluted EPS decreased 26% to $4.81, while adjusted EPS decreased 28% to $5.53, including an estimated 90-cent headwind from ERP-related shipment timing. Net cash provided by operations was $612 million, down from $981 million, primarily due to the Glad venture-termination payment, while adjusted free cash flow was $881 million. Clorox expects fiscal 2027 net sales to grow 13%–14%, including about 9.5 points from GOJO, and guides diluted EPS to $5.41–$5.71 and adjusted EPS to $5.70–$6.00, aided by lapping the ERP inventory drawdown.

Positive

Clorox guides fiscal 2027 diluted EPS up 12% to 19% to $5.41–$5.71, with adjusted EPS expected between $5.70 and $6.00 and organic sales growth of about 3.5% to 4.5%.

Negative

Fiscal 2026 diluted EPS decreased 26% to $4.81, and adjusted EPS fell 28% to $5.53, as gross margin declined 290 basis points to 42.3% versus the prior year.
Net cash provided by operations declined 38% to $612 million from $981 million, while reported net sales fell 5% to $6.72 billion for fiscal 2026.

Filing Explained

At June 30, Clorox reported liabilities against total stockholders’ equity.

The August 3 filing reports fiscal 2026 results through June 30, 2026 and shows the company’s balance-sheet structure at that date.

The filing reports total liabilities against total stockholders’ equity, including equity attributable to Clorox stockholders.

Cash and cash equivalents were lower at June 30 than in the latest quarterly record at March 31, 2026; the filing also reports notes and loans payable as a current liability.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Fiscal 2026 net sales: $6.72 billion Fiscal 2026 diluted EPS (GAAP): $4.81 Fiscal 2026 adjusted EPS (non-GAAP): $5.53 +4 more

7 metrics

Fiscal 2026 net sales $6.72 billion Net sales decreased 5% versus fiscal year 2025

Fiscal 2026 diluted EPS (GAAP) $4.81 Decreased 26% from $6.52 in the prior year

Fiscal 2026 adjusted EPS (non-GAAP) $5.53 Decreased 28% from $7.72 in fiscal year 2025

Net cash provided by operations FY26 $612 million Down from $981 million in fiscal year 2025

Adjusted free cash flow FY26 $881 Adjusted free cash flow in dollars in millions; 13.1% of net sales

FY27 net sales growth outlook 13% to 14% Expected increase versus fiscal year 2026, including about 9.5 points from GOJO

FY27 diluted EPS outlook (GAAP) $5.41 to $5.71 Projected year-over-year increase of 12% to 19%

Key Terms

organic sales growth / (decrease), ERP system transition, inventory step-up, adjusted EBIT, +1 more

5 terms

organic sales growth / (decrease) financial

""Organic sales growth / (decrease) is defined as net sales growth / (decrease) excluding...""

ERP system transition technical

"Retailers placed orders in advance of the company’s ERP system transition in the U.S."

inventory step-up financial

"The negative impact from GOJO transaction-related costs was about 50 basis points, primarily behind inventory step-up."

An inventory step-up is an accounting adjustment made when a business acquisition revalues the purchased company's unsold goods from their old book cost to their current market or fair value, raising the recorded value of that inventory on the balance sheet. This matters to investors because the higher starting value changes future reported profit margins and tax timing—like resetting the price tags in a store, it can make near-term profits look lower even though it doesn't change actual cash sales.

adjusted EBIT financial

"Adjusted EBIT is a non-GAAP measure."

Adjusted EBIT is a company’s operating profit before interest and taxes, but cleaned up by removing one-time or unusual items that can obscure ongoing performance. Investors use it like a tidied-up report card — it aims to show the underlying profitability of the business by excluding irregular gains, losses, or costs so comparisons across periods or companies are clearer and more meaningful for valuing operational strength.

digital capabilities and productivity enhancements investment financial

"Expenses related to the company’s digital capabilities and productivity enhancements investment."

Earnings Snapshot

FY26 net sales: $6.72 billion · Guidance included

Fourth quarter and fiscal year ended June 30, 2026

FY26 net sales $6.72 billion decreased 5% versus fiscal 2025

FY26 diluted EPS (GAAP) $4.81 decreased 26% from $6.52

FY26 adjusted EPS (non-GAAP) $5.53 decreased 28% from $7.72

Guidance

For fiscal 2027, net sales are expected to grow 13% to 14%, including about 9.5 points from the GOJO acquisition, with diluted EPS of $5.41 to $5.71 and adjusted EPS of $5.70 to $6.00.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Available on EDGAR 08/03/2026 - 04:12 PM Accepted by SEC EDGAR 08/03/2026 - 04:12 PM

FAQ

What were Clorox (CLX) net sales and EPS for fiscal 2026?

Clorox reported fiscal 2026 net sales of $6.72 billion, down 5% year over year, and diluted EPS of $4.81, a 26% decrease from $6.52. Adjusted EPS fell 28% to $5.53 from $7.72.

How did Clorox (CLX) perform in Q4 fiscal 2026?

In Q4 fiscal 2026, Clorox’s net sales decreased 2% to $1.95 billion, with organic sales down 13%. Diluted EPS declined 50% to $1.34, and adjusted EPS dropped 42% to $1.66 as gross margin fell to 41.3%.

What impact did the GOJO acquisition and ERP transition have on Clorox (CLX)?

The GOJO acquisition added about 3 points to fiscal 2026 net sales and about 10 points to Q4 sales growth but pressured gross margin via inventory step-up costs. ERP-related shipment timing reduced fiscal 2026 organic sales by about 7.5 points and EPS by roughly $0.90.

What is Clorox (CLX) guiding for fiscal 2027 sales and EPS?

For fiscal 2027, Clorox expects net sales to rise 13%–14%, including about 9.5 points from GOJO, and organic sales to grow about 3.5%–4.5%. Diluted EPS is projected at $5.41–$5.71 and adjusted EPS at $5.70–$6.00.

How did Clorox (CLX) cash flow and free cash flow look in fiscal 2026?

Net cash provided by operations was $612 million, down from $981 million, mainly due to the Glad venture-termination payment. Adjusted free cash flow was $881 (dollars in millions), representing 13.1% of net sales versus 10.7% in fiscal 2025.

How did Clorox (CLX) segments perform in fiscal 2026?

In fiscal 2026, Health and Wellness organic sales declined 8%, Household fell 11%, Lifestyle dropped 14%, and International organic sales grew 2%. Reported International net sales increased 5%, while total company organic sales decreased 8%.

What shape is Clorox’s (CLX) balance sheet in after fiscal 2026?

At June 30, 2026, Clorox had total assets of $7.79 billion and total liabilities of $7.54 billion, including $3.98 billion of long-term debt and $1.09 billion of notes and loans payable, with total stockholders’ equity of $252 million.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 3, 2026

THE CLOROX COMPANY
(Exact name of registrant as specified in its charter)
__________________


Delaware	1-07151	31-0595760
(State or other jurisdiction of	(Commission File Number)	(I.R.S. Employer
incorporation)		Identification No.)

1221 Broadway, Oakland, California 94612-1888
(Address of principal executive offices) (Zip code)

(510) 271-7000
(Registrant's telephone number, including area code)

Not applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


[ ]			Written communications pursuant to Rule 425 Under the Securities Act (17 CFR 230.425)

[ ]			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ]			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ]			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock - $1.00 par value	CLX	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition

On August 3, 2026, The Clorox Company issued a press release announcing its financial results for its fourth quarter and fiscal year ended June 30, 2026. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 7.01 Regulation FD Disclosure

Attached hereto as Exhibit 99.2 and incorporated herein by reference is supplemental financial information.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

See the Exhibit Index below.

EXHIBIT INDEX


Exhibit						Description
99.1						Press Release dated August 3, 2026 of The Clorox Company
99.2						Supplemental information regarding financial results
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


		THE CLOROX COMPANY


Date:	August 3, 2026	By:	/s/ Angela Hilt
			Angela Hilt
			Executive Vice President – Chief Legal and External Affairs Officer and Corporate Secretary

Clorox Reports Q4 and FY26 Results, Provides FY27 Outlook

Delivers Q4 results in line with expectations while advancing strategic investments

OAKLAND, California, Aug. 3, 2026 — The Clorox Company (NYSE: CLX) today reported results for the fourth quarter and fiscal year 2026, which ended June 30, 2026.

Fourth-Quarter Fiscal Year 2026 Summary

In April 2026, the company completed the acquisition of GOJO Industries, Inc. (GOJO), which now operates as Clorox Purell and includes the Purell® brand and a portfolio of health and hygiene solutions.

The following is a summary of key fourth-quarter results. All comparisons are with the fourth quarter of fiscal year 2025 unless otherwise stated.

•Net sales decreased 2% to $1.95 billion. The GOJO acquisition added about 10 points. Organic sales1 decreased 13%, primarily due to lapping the incremental shipments related to the ERP transition, which is about 13.5 points.

•Gross margin decreased 520 basis points to 41.3% from 46.5%, primarily driven by lower volume, impact from the inventory step-up of the GOJO acquisition, higher commodity costs and higher manufacturing and logistics costs, partially offset by cost savings. The ERP-related shipment comparison and GOJO inventory step-up each reduced gross margin by about 150 basis points.

•Diluted net earnings per share (diluted EPS) decreased 50% to $1.34 from $2.68 in the year-ago quarter. The decrease includes GOJO transaction-related costs primarily related to inventory step-up and integration costs, partially offset by the impact of lapping of the company's investment in its digital capabilities and productivity enhancements compared to the prior period.

•Adjusted EPS1 decreased 42% to $1.66 from $2.87 in the year-ago quarter, primarily due to lower net sales and lower gross margin. The impact of ERP-related shipment comparison was about 90 cents.

"Our fourth-quarter results were in line with our expectations and reflect disciplined execution in a dynamic environment," said Chair and CEO Linda Rendle. "Throughout fiscal year 2026, we strengthened our business despite continued consumer and macroeconomic pressures. We expanded our portfolio through the acquisition of GOJO Industries, completed our U.S. ERP implementation, a foundational modernization of the systems and processes that underpin every aspect of our operations, while advancing our digital capabilities. Together, these actions have strengthened our foundation and position us well to navigate a challenging operating environment as we work to return to organic sales growth. We exited the year with improved execution, a stronger innovation pipeline and a clear plan to deliver superior value across our portfolio, better meeting evolving consumer needs and driving long-term growth.

As we begin fiscal year 2027, we expect the operating environment to remain challenging, with continued cost volatility and a value-seeking consumer. Even so, we are starting the year from a stronger position to execute our strategy with discipline, build on the momentum we've created and deliver greater superiority across our portfolio. We are confident that the investments we've made in our brands, capabilities and products position us to deliver long-term value for shareholders."

This press release includes certain Non-GAAP financial measures. See "Non-GAAP Financial Information" at the end of this press release for more details.

1 Organic sales growth/(decrease) and adjusted EPS are non-GAAP measures. See Non-GAAP Financial Information at the end of this press release for reconciliations to the most comparable GAAP measures.

Strategic and Operational Highlights

The following are highlights of business achievements for fiscal year 2026:

•Completed the acquisition of GOJO, unlocking new growth synergies across the combined portfolio of Clorox Purell and Clorox Professional by bringing together complementary brands and capabilities to strengthen the company's health and hygiene platform. Clorox’s global health and hygiene portfolio now represents more than half of net sales.

•Continued to invest behind value superiority and consumer-centered experiences by nearly doubling innovation across its expanded portfolio in fiscal year 2026, including the launch of Clorox PURE and Clorox Screen+ Sanitizing Wipes, expanded professional hygiene solutions from Clorox Healthcare and Purell, Fresh Step Lightweight Litter, Glad ForceFlex MaxStrength LeakGuard Trash Bags, new lip and body care offerings from Burt’s Bees, as well as new flavors and scents across Clorox, Glad, Hidden Valley Ranch and Pine-Sol.

•Completed its U.S. ERP implementation, marking the conclusion of the company's five-year digital transformation investment, modernizing the business to optimize operations and reduce costs by leveraging end-to-end data and insights to support decision-making.

•Implemented a simplified operating structure to streamline leadership oversight, align resources to drive the company's strongest growth opportunities, advance portfolio optimization efforts and support faster execution across the enterprise.

•The company was recognized among America's Best Companies by Time Magazine, as well as America’s Best Employers for Company Culture and 2026 Net Zero Leaders by Forbes.

Key Segment Results

The following is a summary of key fourth-quarter results by reportable segment. All comparisons are with the fourth quarter of fiscal year 2025, unless otherwise stated.

Health and Wellness (Cleaning; Professional Products, now including Clorox Purell)

•Net sales increased 16%, driven by 10 points of higher volume and 6 points of favorable price mix. The GOJO acquisition contributed approximately 28 points to net sales growth. Organic sales declined 12%, primarily driven by the impact of lapping the incremental shipments related to the ERP transition in the year-ago quarter. Excluding the impact of these incremental shipments, organic sales would have increased in the quarter.

•Segment adjusted EBIT2 decreased 15%, primarily due to the impact of lapping the incremental shipments related to the ERP transition in the year-ago quarter, higher advertising investments and manufacturing and logistics costs, partially offset by the benefit of the GOJO acquisition.

Household (Bags and Wraps; Cat Litter; Grilling)

•Net sales decreased 18%, driven by 16 points of lower volume and 2 points of unfavorable price mix. The volume decrease is primarily due to the impact of lapping the incremental shipments related to the ERP transition in the year-ago quarter and shipment ahead of consumption in the third quarter.

•Segment adjusted EBIT decreased 56%, primarily due to lower net sales and higher commodity costs, partially offset by cost savings.

Lifestyle (Food; Water Filtration; Natural Personal Care)

2 Adjusted EBIT is a non-GAAP measure. See Non-GAAP Financial Information at the end of this press release for reconciliations to the most comparable GAAP measures.

Page 2 of 17

•Net sales decreased 17%, driven by 14 points of lower volume and 3 points of unfavorable price mix. The volume decrease is primarily due to the impact of lapping the incremental shipments related to the ERP transition in the year-ago quarter.

•Segment adjusted EBIT decreased 60%, primarily due to lower net sales.

International (Sales Outside the U.S.)

•Net sales increased 4%, primarily driven by favorable foreign exchange rates. Organic sales grew 1%.

•Segment adjusted EBIT increased 17%, primarily due to higher net sales and cost savings.

Fiscal Year 2026 Summary

The following is a summary of key fiscal year 2026 results. All comparisons are to fiscal year 2025.

•Net sales decreased 5% to $6.72 billion. The GOJO acquisition added about 3 points. Organic sales decreased 8%, mainly due to lapping incremental shipments related to the ERP transition in the fourth quarter, which is about 7.5 points.

•Gross margin decreased 290 basis points to 42.3% from 45.2% in the year-ago period, primarily driven by lower net sales and higher manufacturing and logistics costs, partially offset by cost savings. The ERP-related shipment comparison reduced gross margin by about 100 basis points. The negative impact from GOJO transaction-related costs was about 50 basis points, primarily behind inventory step-up.

•Diluted EPS decreased 26% to $4.81 from $6.52 in the year-ago period, which includes lapping the cyberattack insurance recovery benefit from the prior period, GOJO transaction-related costs primarily related to inventory step-up and integration costs, partially offset by lower costs related to the company's investment in its digital capabilities and productivity enhancements in the current period and the loss on sale of the VMS business in the prior period.

•Adjusted EPS decreased 28% to $5.53 from $7.72, primarily due to lower net sales and higher manufacturing and logistics costs, partially offset by cost savings. The ERP-related shipment comparison reduced adjusted EPS by about 90 cents.

•Net cash provided by operations was $612 million compared to $981 million in fiscal year 2025, representing a 38% decrease. The decrease was primarily driven by the Glad Venture Agreement termination payment.

Page 3 of 17

ERP Transition Impact

During the fourth quarter of fiscal year 2025, retailers placed orders in advance of the company's ERP system transition in the U.S. to minimize any potential inventory impacts during the implementation phase. The shipments of incremental inventory provided a benefit to fourth quarter 2025 net sales. These shipments added about 3.5 points of sales and about 90 cents earnings per share to fiscal year 2025.

In fiscal year 2026, retailers drew down on this inventory during the company's ERP transition period, resulting in lower shipments. From a year-over-year sales growth perspective, the reduction in sales from this inventory drawdown translates to about 7.5 points of decline as compared to the higher base in fiscal year 2025. Similarly, this inventory drawdown reduced fiscal year 2026 earnings per share by about 90 cents. In comparison to the higher base in fiscal year 2025, this results in a year-over-year reduction of about 28% to fiscal year 2026 diluted earnings per share and about 23% to fiscal year 2026 adjusted earnings per share.

In fiscal year 2027, the company will lap the above-described inventory drawdown, which is expected to result in more than 3.5 points of benefit to net sales growth. This lap is also expected to benefit the company’s adjusted EPS growth.

Fiscal Year 2027 Outlook

The following are the key drivers of the company’s fiscal year 2027 outlook:

•Net sales are expected to be up 13% to 14% compared to the prior year, including about 9.5 points of benefit from the GOJO acquisition. Organic sales are expected to increase about 3.5% to 4.5%, including more than 3.5 points of benefit from lapping the ERP-related drawdown in the prior fiscal year.

•Gross margin is expected to be about 42%, reflecting higher-than-normal inflationary headwinds and negative mix more than offsetting the benefits from cost savings. This includes about 20 basis points of negative impact primarily related to the GOJO inventory step-up.

•Selling and administrative expenses are expected to be about 16% of net sales. This includes about 40 basis points of negative impact from GOJO transaction-related costs.

•Advertising and sales promotion spending is expected to be about 10% of net sales. This assumes over 11% of net sales for its retail businesses.

•The company's effective tax rate is expected to be about 23%.

•Diluted EPS is expected to be between $5.41 and $5.71, a year-over-year increase of 12% to 19%, respectively. This includes about 29 cents of impact from transaction-related costs associated with the GOJO acquisition, which are expected to flow through cost of goods sold as well as selling and administrative expenses.

•Adjusted EPS is expected to be between $5.70 and $6.00, or an increase between 3% and 8%, respectively. These growth rates include the benefit of lapping the inventory drawdown related to the ERP transition in the prior year.




Net sales (percentage change versus the year-ago period)
	Fiscal year 2025 full year		Fiscal year 2026 full year		Fiscal year 2027 full year outlook
	Impact		Impact		Low		High
Net sales growth / (decrease) (GAAP)	0	%	(5)	%	13	%	14	%

Add/(Subtract): Divestitures/acquisitions	5		(3)		(9.5)		(9.5)
Organic sales growth / (decrease) (non-GAAP)	5	%	(8)	%	3.5	%	4.5	%

Page 4 of 17




Note: Approximate impact from incremental shipments related to ERP transition	3.5	%	(7.5)	%	>3.5%	>3.5%



Diluted earnings per share
	Fiscal year 2025 full year		Fiscal year 2026 full year		Fiscal year 2027 full year outlook
	Impact		Impact		Low		High
As estimated (GAAP)	$	6.52	$	4.81	$	5.41	$	5.71
Loss on divestiture	0.94				—		—
Acquisition and integration costs	—		0.36		0.29		0.29
Cyberattack costs, net of insurance recoveries	(0.42)				—		—
Digital capabilities and productivity enhancements investment	0.68		0.36		—		—
As adjusted (non-GAAP)	$	7.72	$	5.53	$	5.70	$	6.00


Note: Approximate impact from incremental shipments related to ERP transition	$	0.90	$	(0.90)	$	—	$	—

Clorox Earnings Conference Call Schedule

At approximately 4:15 p.m. ET today, Clorox will post prepared management remarks regarding its fourth-quarter and fiscal year 2026 results.

At 5 p.m. ET today, the company will host a live Q&A audio webcast with Chair and CEO Linda Rendle and Chief Financial Officer Luc Bellet to discuss the results.

Links to the live (and archived) webcast, press release and prepared remarks can be found at Clorox Quarterly Results.

For More Detailed Financial Information

Visit the company’s Quarterly Results for the following:

•Supplemental unaudited volume and sales growth information

•Supplemental unaudited gross margin drivers information

•Supplemental unaudited cash flow information and free cash flow reconciliation

•Supplemental unaudited reconciliation of earnings (losses) before income taxes to EBIT and adjusted EBIT

•Supplemental unaudited reconciliation of adjusted earnings per share (EPS) and adjusted effective tax rate (ETR)

Note: Percentage and basis-point, or point, changes noted in this press release are calculated based on rounded numbers, except for per-share data and the effective tax rate.

About The Clorox Company

The Clorox Company (NYSE: CLX) champions people to be well and thrive every single day. Headquartered in Oakland, California since 1913, Clorox integrates sustainability into how it does business. Driven by consumer-centric innovation, the company is committed to delivering clearly superior experiences through its trusted brands including Brita®, Burt's Bees®, Clorox®, Fresh Step®, Glad®, Hidden Valley®, Kingsford®, Liquid-Plumr®, PineSol® and Purell® as well as international brands such as Chux®, Clorinda® and Poett®. Visit thecloroxcompany.com to learn more.

Page 5 of 17

Media Relations

corporate.communications@clorox.com

Investor Relations

investorrelations@clorox.com

CLX-F

Page 6 of 17

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, among others, regarding the acquisition of GOJO, and any such forward-looking statements involve risks, assumptions and uncertainties. Except for historical information, statements about future volumes, sales, organic sales growth, foreign currencies, costs, cost savings, margins, earnings, earnings per share, including as a result of the GOJO acquisition, diluted earnings per share, foreign currency exchange rates, tax rates, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management's estimates, beliefs, assumptions and projections. Words such as "could," "may," "expects," "anticipates," "targets," "goals," "projects," "intends," "plans," "believes," "seeks," "estimates," "will," "predicts," and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance are intended to identify such forward-looking statements. These forward-looking statements are only predictions, subject to risks and uncertainties, and actual results could differ materially from those discussed. Important factors that could affect performance and cause results to differ materially from management's expectations, are described in the sections entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's Annual Report on Form 10-K for the fiscal year ended June 30, 2025, as updated from time to time in the company's Securities and Exchange Commission filings. These factors include, but are not limited to: the risks arising from the integration of the GOJO business, including the ability to successfully integrate GOJO’s operations, systems, controls, culture, customers, suppliers and personnel, and to realize the anticipated benefits and synergies of the acquisition, including cost savings and growth opportunities, when expected or at all; the risks of adapting to GOJO’s business-to-business (“B2B”) operating model, including differences in distribution channels, go-to-market strategies, margin profiles and customer requirements, increased exposure to customer concentration and consolidation among distributors, group purchasing organizations, health systems and other institutional customers in B2B channels, and potential channel conflict with the company’s consumer business; the risk of increased regulatory exposure resulting from GOJO’s portfolio of products subject to U.S. Food and Drug Administration oversight, including products regulated as cosmetics and over-the-counter drugs; the risk of unexpected costs or expenses resulting from the GOJO acquisition; the risk of litigation related to the GOJO acquisition, including resulting expense; the risk of impairment charges related to intangible assets acquired in connection with the GOJO acquisition; the risks related to disruption of the company’s ongoing business operations and diversion of management time and resources from the GOJO acquisition; the risk that the GOJO acquisition may have an adverse effect on the company’s ability to retain key personnel, customers and suppliers; unfavorable general economic and geopolitical conditions beyond the company’s control, including inflation, supply chain disruptions, labor shortages, wage pressures, fuel and energy costs, interest rate fluctuations, foreign currency exchange rate fluctuations, weather events or natural disasters, disease outbreaks or pandemics, terrorism, and unstable geopolitical conditions, including active armed conflicts and military hostilities in the Middle East, such as the ongoing conflict involving Iran, and rising tensions in various parts of the world, as well as macroeconomic and geopolitical volatility and uncertainty resulting from a number of these and other factors, such as actual and potential shifts in U.S. and foreign trade policies, escalating trade tensions between the U.S. and its trading partners, especially China, the potential expansion of sanctions regimes, and disruptions to global markets or transportation routes, particularly due to the imposition of U.S. and retaliatory tariffs; the impact of market and category declines, and the company’s product and geographic mix on its ability to meet sales growth targets; the company’s ability to successfully execute or realize the anticipated benefits of its strategic or transformational initiatives, including the ERP transition and the related timing and volume of shipment movement related to the ERP transition and the shift towards a simplified operating structure; the impact of the changing retail environment, including the growth of alternative retail channels and business models, and changing consumer preferences; intense competition in the company’s markets; volatility and increases in the costs of raw materials, energy, transportation, labor and other necessary supplies or services; risks related to supply chain issues, product shortages and disruptions to the business, as a result of increased supply chain dependencies due to an expanded supplier network and a reliance on certain single-source suppliers; risks related to the company’s use of and reliance on information technology systems, including potential and actual security breaches, cyberattacks, privacy breaches or data breaches that result in the unauthorized disclosure of consumer, customer, employee or company information, business, service or operational disruptions, or that impact the company’s financial results or financial reporting, or any resulting unfavorable outcomes, increased costs or legal proceedings; the ability of the company to innovate and to develop and introduce commercially successful products, or expand into adjacent

Page 7 of 17

categories and countries; the ability of the company to successfully manage global political, legal, tax and regulatory risks, including due to regulatory uncertainty and lack of regulatory convergence among different jurisdictions; lower revenue, increased costs, other financial statement impacts or reputational harm resulting from government actions, compliance with regulations, or any material costs imposed by changes in regulation; the company’s ability to maintain its business reputation and the reputation of its brands and products; dependence on key customers and risks related to customer consolidation and ordering patterns; the company’s ability to attract and retain key personnel, which may continue to be impacted by challenges in the labor market, such as increasing labor costs and sustained labor shortages, as well as the company’s ability to manage leadership transitions, including the previously announced CEO succession, and retain and integrate key employees of acquired businesses; changes to the company’s processes and procedures as a result of its digital capabilities and productivity enhancements that may result in changes to the company’s internal controls over financial reporting; risks related to the company’s continued operation of the Glad business; risks related to international operations and international trade, including changing macroeconomic conditions as a result of inflation, volatile commodity prices and increases in raw and packaging materials prices, labor, energy and logistics; global economic or political instability; foreign currency fluctuations, such as devaluations, and foreign currency exchange rate controls; changes in governmental policies, including trade policy and tariffs, travel or immigration restrictions, new or additional tariffs, and price or other controls; labor claims and civil unrest; potential operational or supply chain disruptions from wars and military conflicts, including active armed conflicts and military hostilities in the Middle East, such as the ongoing conflict involving Iran, and/or Ukraine and rising tensions in various parts of the world, such as between China and Taiwan; potential negative impact and liabilities from the use, storage and transportation of chlorine in certain international markets where chlorine is used in the production of bleach; widespread health emergencies; and the possibility of nationalization, expropriation of assets or other government action or inaction, including the impacts of any prolonged U.S. government shutdown; the impact of climate change and other sustainability issues on sales, operating costs, reputation or stakeholder relationships; the impact of product liability claims, labor claims and other legal, governmental or tax proceedings, including in foreign jurisdictions and in connection with any product recalls; risks relating to acquisitions, new ventures and divestitures, and associated costs, including for asset impairment charges related to, among others, intangible assets, including trademarks and goodwill, and integration costs and potential contingent liabilities related to those transactions; the accuracy of the company’s estimates and assumptions on which its financial projections, including any sales or earnings guidance or outlook it may provide from time to time, are based; risks related to the company's reliance on third-party service providers, including inability to meet cost savings or efficiencies, business or systems disruptions, and other liabilities, including legal or regulatory risk; environmental matters, including costs associated with the remediation and monitoring of past contamination, and possible increases in costs resulting from actions by relevant regulators, and the handling and/or transportation of hazardous substances; the company’s ability to effectively utilize, assert and defend its intellectual property rights, and any infringement or claimed infringement by the company of third-party intellectual property rights; the effect of the company’s indebtedness and credit rating, including increased indebtedness resulting from the GOJO acquisition and Glad joint venture buyout, on its business operations and financial results and the company’s ability to access capital markets and other funding sources, as well as the cost of capital to the company; the company’s ability to pay and declare dividends or repurchase its stock in the future; and the impacts of potential stockholder activism.

The company's forward-looking statements in this press release are based on management's current views, beliefs, assumptions and expectations regarding future events and speak only as of the date of this press release. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the federal securities laws.

Non-GAAP Financial Information

•This press release contains non-GAAP financial information related to organic sales growth / (decrease), adjusted EPS, and segment adjusted EBIT for the fourth quarter of fiscal year 2026 and for fiscal year 2026; as well as organic sales growth / (decrease) and adjusted EPS outlook for fiscal year 2027. The reasons management believes these measures are useful to investors are described below. Certain non-GAAP financial measures may be considered in determining incentive compensation.

•Clorox defines organic sales growth / (decrease) as GAAP net sales growth / (decrease) excluding the effect of foreign exchange rate changes and any acquisitions or divestitures.

Page 8 of 17

•Management believes that the presentation of organic sales growth / (decrease) is useful to investors because it excludes sales from any acquisitions and divestitures, which results in a comparison of sales only from the businesses that the company was operating and expects to continue to operate throughout the relevant periods, and the company's estimate of the impact of foreign exchange rate changes, which are difficult to predict and out of the control of the company and management. However, organic sales growth / (decrease) may not be the same as similar measures provided by other companies due to potential differences in methods of calculation or differences in which items are incorporated into these adjustments.

•Organic Sales, Adjusted Cost of Products Sold, Adjusted Gross Profit, Adjusted Gross Margin, Adjusted Selling and Administrative expenses, Adjusted Other Income (Expense), Adjusted Net Earnings Attributable to Clorox, and Adjusted Diluted Net Earnings Per Share are calculated in accordance with GAAP, that excludes or has otherwise been adjusted for significant items that are nonrecurring or unusual that are not indicative of the Company’s underlying operations. The income tax effect on non-GAAP items is calculated based upon the tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment. Non-GAAP measures may not be the same as similar measures provided by other companies due to potential differences in methods of calculation or differences in which items are incorporated into these adjustments.

•Adjusted EBIT represents earnings (losses) before income taxes excluding interest income, interest expense and other significant items that are nonrecurring or unusual that are not indicative of the Company’s underlying operations. The company uses this measure to assess the operating results and performance of its segments, perform analytical comparisons, identify strategies to improve performance, and allocate resources to each segment. Adjusted EBIT may not be the same as similar measures provided by other companies due to potential differences in methods of calculation or differences in which items are incorporated into these adjustments.

•The Non-GAAP measures listed above are supplemental information that management uses to help evaluate the company's historical and prospective financial performance on a consistent basis over time. Management believes that by adjusting for certain items affecting comparability of performance over time, such as the pension settlement charge, incremental costs and insurance recoveries related to the August 2023 cyberattack, asset impairments, charges related to the digital capabilities and productivity enhancements investment, transaction and integration costs related to acquisitions, significant losses related to divestitures and other nonrecurring or unusual items, investors and management are able to gain additional insight into the company's underlying operating performance on a consistent basis over time.

Page 9 of 17

•The reconciliation tables below refer to the equivalent GAAP measures adjusted as applicable for the following items:

Acquisition and Integration Costs

On April 1, 2026, the Company completed the previously announced acquisition of GOJO Industries. As a result of this transaction, various acquisition and integration-related costs were and will be incurred related to the acquisition and efforts to integrate the recently acquired business to the Company’s systems and processes. These costs include inventory step-up charges representing expense recognition of fair value adjustments in excess of the historical cost basis of inventory obtained through the acquisition, as well as direct acquisition transaction costs and legal-entity, operational, manufacturing, and information technology integration costs.

Due to the nature, scope and magnitude of these costs and recoveries, the company's management believes presenting these costs as an adjustment in the non-GAAP results provides additional information to investors about trends in the company's operations and is useful for period over period comparisons. It also allows investors to view underlying operating results in the same manner as they are viewed by company management.

Digital Capabilities and Productivity Enhancements Investment

As announced in August 2021, the company invested in transformative technologies and processes over a five-year period beginning in fiscal year 2022 and completed during the third quarter of fiscal year 2026. The investment included replacement of the company's ERP system and transitioning to a cloud-based platform as well as the implementation of a suite of other digital technologies. The total incremental transformational investment was approximately $580 million. It is expected that these implementations will generate efficiencies and transform the company's operations in the areas of supply chain, digital commerce, innovation, brand building and more over the long term.

Of the total investment, approximately 75% represented incremental operating costs primarily recorded within selling and administrative expenses to be adjusted from reported EPS for purposes of disclosing adjusted EPS. About 70% of these operating costs were related to the implementation of the ERP, with the remaining costs primarily related to the implementation of complementary technologies.

Due to the nature, scope and magnitude of this investment, these costs were considered by management to represent incremental transformational costs above the historical normal level of spending for information technology to support operations. Since these strategic investments, including incremental operating costs, ceased at the end of the investment period, are not expected to recur in the foreseeable future and are not considered representative of the company's underlying operating performance, the company's management believes presenting these costs as an adjustment in the non-GAAP results provides additional information to investors about trends in the company's operations and is useful for period-over-period comparisons. It also allows investors to view underlying operating results in the same manner as they are viewed by company management.

The following tables provide reconciliations of organic sales growth/(decrease) (non-GAAP) to net sales growth/(decrease), the most comparable GAAP measure:

Page 10 of 17



	Three months ended June 30, 2026
	Percentage change versus the year-ago period
	Health and Wellness		Household		Lifestyle		International		Total Company (1)
Net sales growth / (decrease) (GAAP)	16	%	(18)	%	(17)	%	4	%	(2)	%
Add: Foreign Exchange	—		—		—		(3)		(1)
Add/(Subtract): Divestitures/Acquisitions (2)	(28)		—		—		—		(10)
Organic sales growth / (decrease) (non-GAAP)	(12)	%	(18)	%	(17)	%	1	%	(13)	%



	Twelve months ended June 30, 2026
	Percentage change versus the year-ago period
	Health and Wellness		Household		Lifestyle		International		Total Company (1)
Net sales growth / (decrease) (GAAP)	—	%	(11)	%	(14)	%	5	%	(5)	%
Add: Foreign Exchange	—		—		—		(3)		—
Add/(Subtract): Divestitures/Acquisitions (2)	(8)		—		—		—		(3)
Organic sales growth / (decrease) (non-GAAP)	(8)	%	(11)	%	(14)	%	2	%	(8)	%

(1)Total Company includes Corporate and Other. Corporate and Other includes the results of the Better Health VMS business through the date of divestiture.

(2)The divestiture impact is calculated as net sales from the Better Health VMS business after the sale date in the twelve month year-ago period. The acquisition impact is calculated as net sales from GOJO after the acquisition date in the current three and twelve month periods.

Page 11 of 17

The following tables provide reconciliations of adjusted non-GAAP line items to the most comparable GAAP measure:


Reconciliation of Non-GAAP Measures
	Three months ended June 30, 2026
	As Reported GAAP			Acquisition and integration costs		Adjusted (non-GAAP)
Cost of products sold	$	1,144		$	(30)	$	1,114
Gross profit	804			30		834
Gross margin	41.3		%			42.8		%

Selling and administrative expenses	298			(21)		277
Percent of net sales	15.3		%			14.2		%

Other (income) expense, net	(10)			—		(10)

Net earnings attributable to Clorox	163			39		202

Diluted net earnings per share	$	1.34		$	0.32	$	1.66


Reconciliation of Non-GAAP Measures
	Twelve months ended June 30, 2026
	As Reported GAAP			Acquisition and integration costs		Digital capabilities and productivity enhancements investment		Adjusted (non-GAAP)
Cost of products sold	$	3,876		$	(31)	$	—	$	3,845
Gross profit	2,844			31		—		2,875
Gross margin	42.3		%					42.8		%

Selling and administrative expenses	1,066			(27)		(59)		980
Percent of net sales	15.9		%					14.6		%

Other (income) expense, net	(8)			—		—		(8)

Net earnings attributable to Clorox	587			44		45		676

Diluted net earnings per share	$	4.81		$	0.36	$	0.36	$	5.53

Page 12 of 17

The following tables provide reconciliations of adjusted diluted earnings per share (non-GAAP) to diluted earnings per share, the most comparable GAAP measure:


Adjusted Diluted Earnings Per Share (EPS)
(Dollars in millions except per share data)

		Diluted earnings per share
		Three months ended
		6/30/2026		6/30/2025		% Change
	As reported (GAAP)	$	1.34	$	2.68	(50)	%

	Acquisition and integration costs (2)	0.32		—

	Digital capabilities and productivity enhancements investment (4)	—		0.19
	As adjusted (Non-GAAP)	$	1.66	$	2.87	(42)	%

		Diluted earnings per share
		Twelve months ended
		6/30/2026		6/30/2025		% Change
	As reported (GAAP)	$	4.81	$	6.52	(26)	%
	Loss on divestiture (1)	—		0.94
	Acquisition and integration costs (2)	0.36		—
	Cyberattack costs, net of insurance recoveries (3)	—		(0.42)
	Digital capabilities and productivity enhancements investment (4)	0.36		0.68
	As adjusted (Non-GAAP)	$	5.53	$	7.72	(28)	%

	(1)During the twelve months ended June 30, 2025, the company incurred an after tax charge of $118 related to the divestiture of the Better Health VMS business.
	(2)During the three and twelve months ended June 30, 2026, the company incurred approximately $51 ($39 after tax) and $58 ($44 after tax), respectively of costs related to the GOJO acquisition.
	(3)During the twelve months ended June 30, 2025, the company recognized approximately $70 ($53 after tax) of insurance recoveries related to the cyberattack.

	(4)During the three and twelve months ended June 30, 2026, the company incurred $0 and approximately $59 ($45 after tax), respectively, and during the three and twelve months ended June 30, 2025, the company incurred approximately $30 ($23 after tax) and $111 ($85 after tax), respectively, of operating expenses related to its digital capabilities and productivity enhancements investment. The expenses relate to the following:



	Three months ended				Twelve months ended
	6/30/2026		6/30/2025		6/30/2026		6/30/2025
External consulting fees (a)	$	—	$	22	$	46	$	78
IT project personnel costs (b)	—		2		3		7
Other (c)	—		6		10		26
Total	$	—	$	30	$	59	$	111

(a)Comprised of third-party consulting fees incurred to assist in the project management and end-to-end systems integration of this transformative investment. The company relies on consultants for certain capabilities required for these programs that the company does not maintain internally. These costs support the implementation of these programs incremental to the company's normal IT costs and will not be incurred following implementation.
(b)Comprised of labor costs associated with internal IT project management teams that are utilized to oversee the new system implementations. Given the magnitude and transformative nature of the implementations planned, the necessary project management costs are incremental to the historical levels of spend and will no longer be incurred subsequent to implementation. As a result of this long-term strategic investment, the company considers these costs not reflective of the ongoing costs to operate its business.
(c)Comprised of various other expenses associated with the company’s new system implementations, including company personnel dedicated to the project that have been backfilled with either permanent or temporary resources in positions that are considered part of normal operating expenses.

Page 13 of 17

The following tables provide reconciliations of adjusted EBIT (non-GAAP) to earnings (losses) before income taxes, the most comparable GAAP measure:


	Reconciliation of earnings (losses) before income taxes to adjusted EBIT
	Three months ended				Twelve months ended
	6/30/2026		6/30/2025		6/30/2026		6/30/2025
Earnings (losses) before income taxes	$	213	$	410	$	791	$	1,078
Interest income	(1)		(2)		(8)		(9)
Interest expense	55		22		130		88
Loss on divestiture	—		—		—		118
Acquisition and integration costs	51		—		58		—
Cyberattack costs, net of insurance recoveries	—		—		—		(70)

Digital capabilities and productivity enhancements investment	—		30		59		111
Adjusted EBIT	$	318	$	460	$	1,030	$	1,316


		Full year 2027 outlook (estimated range)
		Diluted earnings per share
		Low		High
	As estimated (GAAP)	$	5.41	$	5.71
	Acquisition and integration costs (1)	0.29		0.29

	As adjusted (Non-GAAP)	$	5.70	$	6.00

(1)In fiscal year 2027, the company expects to incur approximately $46 ($35 after tax) of costs related to the GOJO acquisition.

Page 14 of 17


Condensed Consolidated Statements of Earnings
Dollars in millions, except per share data
	Three months ended				Twelve months ended
	6/30/2026		6/30/2025		6/30/2026		06/30/2025
	(Unaudited)		(Unaudited)		(Unaudited)

Net sales	$	1,948	$	1,988	$	6,720	$	7,104
Cost of products sold	1,144		1,064		3,876		3,891
Gross profit	804		924		2,844		3,213
Selling and administrative expenses	298		296		1,066		1,124
Advertising costs	216		171		749		770
Research and development costs	32		32		116		121
Loss on divestiture	—		—		—		118


Interest expense	55		22		130		88
Other (income) expense, net	(10)		(7)		(8)		(86)
Earnings before income taxes	213		410		791		1,078
Income taxes	46		74		190		254
Net earnings	167		336		601		824
Less: Net earnings attributable to noncontrolling interests	4		4		14		14
Net earnings attributable to Clorox	$	163	$	332	$	587	$	810

Net earnings per share attributable to Clorox
Basic net earnings per share	$	1.34	$	2.70	$	4.82	$	6.56
Diluted net earnings per share	$	1.34	$	2.68	$	4.81	$	6.52

Weighted average shares outstanding (in thousands)
Basic	121,504		123,173		121,775		123,525
Diluted	121,809		123,744		122,132		124,287

Page 15 of 17


Reportable Segment Information
(Unaudited)
Dollars in millions

	Net sales						Net sales
	Three months ended						Twelve months ended
	6/30/2026		6/30/2025		% Change(1)		6/30/2026		6/30/2025		% Change(1)
Health and Wellness	$	860	$	741	16	%	$	2,697	$	2,697	—	%
Household	524		639		(18)	%	1,787		2,001		(11)	%
Lifestyle	280		339		(17)	%	1,123		1,303		(14)	%
International	281		269		4	%	1,113		1,065		5	%
Reportable segment total	$	1,945	$	1,988			$	6,720	$	7,066
Corporate and Other (2)	3		—		100	%	—		38		(100)	%
Total	$	1,948	$	1,988	(2)	%	$	6,720	$	7,104	(5)	%

	Segment adjusted EBIT						Segment adjusted EBIT
	Three months ended						Twelve months ended
	6/30/2026		6/30/2025		% Change(1)		6/30/2026		6/30/2025		% Change(1)
Health and Wellness	$	206	$	243	(15)	%	$	678	$	840	(19)	%
Household	69		156		(56)	%	192		325		(41)	%
Lifestyle	38		94		(60)	%	208		290		(28)	%
International	27		23		17	%	113		110		3	%
Reportable segment total	$	340	$	516			$	1,191	$	1,565
Corporate and Other (2)	(22)		(56)				(161)		(249)

Interest income	1		2				8		9
Interest expense	(55)		(22)				(130)		(88)
Loss on divestiture (3)	—		—				—		(118)
Acquisition and integration costs (4)	(51)		—				(58)		—
Cyberattack costs, net of insurance recoveries (5)	—		—				—		70

Digital capabilities and productivity enhancements investment (6)	—		(30)				(59)		(111)
Earnings (losses) before income taxes	$	213	$	410	(48)	%	$	791	$	1,078	(27)	%

(1)Percentages based on rounded numbers.

(2)Corporate and Other includes the Better Health VMS business.

(3)Represents the loss on divestiture of the Better Health VMS business of $118 after tax for the twelve months ended June 30, 2025.

(4)Represents expenses related to the company's acquisition and integration of GOJO of $51 ($39 after tax) and $58 ($44 after tax) for the three and twelve months ended June 30, 2026, respectively.

(5)Represents insurance recoveries related to the cyberattack of approximately $70 ($53 after tax) for the twelve months ended June 30, 2025.

(6)Represents expenses related to the company's digital capabilities and productivity enhancements investment of $0 and $59 ($45 after tax) for the three and twelve months ended June 30, 2026, respectively, and $30 ($23 after tax) and $111 ($85 after tax) for the three and twelve months ended June 30, 2025, respectively.

Page 16 of 17


Condensed Consolidated Balance Sheets
Dollars in millions
			6/30/2026		6/30/2025
			(Unaudited)
ASSETS
Current assets
	Cash and cash equivalents		$	143	$	167
	Receivables, net			791		821
	Inventories, net			777		523
	Prepaid expenses and other current assets			113		97
		Total current assets		1,824		1,608
Property, plant and equipment, net				1,512		1,267
Operating lease right-of-use assets				401		333
Goodwill				1,945		1,229
Trademarks, net				989		502
Other intangible assets, net				606		64
Other assets				517		558
Total assets			$	7,794	$	5,561

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
	Notes and loans payable		$	1,086	$	4
	Current maturities of long-term debt			1		—
	Current operating lease liabilities			86		87
	Accounts payable and accrued liabilities			1,600		1,828

		Total current liabilities		2,773		1,919
Long-term debt				3,981		2,484
Long-term operating lease liabilities				366		305
Other liabilities				405		351
Deferred income taxes				17		20
		Total liabilities		7,542		5,079
Commitments and contingencies
Stockholders’ equity
Preferred stock				—		—
Common stock				131		131
Additional paid-in capital				1,312		1,319
Retained earnings				386		432
Treasury stock				(1,582)		(1,404)
Accumulated other comprehensive net (loss) income				(157)		(157)
		Total Clorox stockholders’ equity		90		321
Noncontrolling interests				162		161
Total stockholders’ equity				252		482
Total liabilities and stockholders’ equity			$	7,794	$	5,561

Page 17 of 17


Three months ended June 30, 2026
Percentage change versus the year-ago period
	Reported (GAAP) Net Sales Growth / (Decrease)	Reported Volume	Acquisitions & Divestitures (1)	Foreign Exchange Impact	Price Mix and Other (2)	Organic Sales Growth / (Decrease) (Non-GAAP) (3)	Organic Volume (4)
Health and Wellness (4)	16%	10%	28%	—%	6%	(12)%	(15)%
Household	(18)	(16)	—	—	(2)	(18)	(16)
Lifestyle	(17)	(14)	—	—	(3)	(17)	(14)
International	4	(1)	—	3	2	1	(1)
Total Company (4)(5)	(2)%	(3)%	10%	1%	—%	(13)%	(13)%


Twelve months ended June 30, 2026
Percentage change versus the year-ago period
	Reported (GAAP) Net Sales Growth / (Decrease)	Reported Volume	Acquisitions & Divestitures (1)	Foreign Exchange Impact	Price Mix and Other (2)	Organic Sales Growth / (Decrease) (Non-GAAP) (3)	Organic Volume (4)
Health and Wellness (4)	—%	(1)%	8%	—%	1%	(8)%	(8)%
Household	(11)	(9)	—	—	(2)	(11)	(9)
Lifestyle	(14)	(12)	—	—	(2)	(14)	(12)
International	5	—	—	3	2	2	—
Total Company (4)(5)	(5)%	(5)%	3%	—%	—%	(8)%	(7)%

(1)The divestiture impact is calculated as net sales from the Better Health VMS business after the sale date in the twelve month year-ago period. The acquisition impact is calculated as net sales from GOJO after the acquisition date in the current three and twelve month periods.

(2)This represents the net impact on net sales growth / (decrease) from pricing actions, mix, trade promotion spending, mix from acquisitions and divestitures and other factors. In the three months ended June 30, 2026, the impact from acquisition mix was 3% and 0% for Health and Wellness and Total Company, respectively. In the twelve months ended June 30, 2026, the impact from acquisition and divestiture mix was 1% for both Health and Wellness and Total Company.

(3)Organic sales growth / (decrease) is defined as net sales growth / (decrease) excluding the effect of any acquisitions and divestitures and foreign exchange rate changes. See below for reconciliation of organic sales growth / (decrease) to net sales growth / (decrease), the most directly comparable GAAP financial information.

Management believes that the presentation of organic sales growth / (decrease) is useful to investors because it excludes sales from any acquisitions and divestitures, which results in a comparison of sales only from the businesses that the company was operating throughout the relevant periods, and the impact of foreign exchange rate changes, which are out of the control of the company and management. However, organic sales growth / (decrease) may not be the same as similar measures provided by other companies due to potential differences in methods of calculation and items being excluded.

(4)Organic volume represents volume excluding the effect of any acquisitions and divestitures. In the three months ended June 30, 2026, the volume impact of the acquisition was 25% and 10% for Health and Wellness and Total Company, respectively. In the twelve months ended June 30, 2026, the volume impact of acquisitions and divestitures was 7% and 2% for Health and Wellness and Total Company, respectively.

(5)Total Company includes Corporate and Other. Corporate and Other includes the results of the Better Health VMS business through the date of divestiture.

The following table provides a reconciliation of organic sales growth / (decrease) (non-GAAP) to net sales growth / (decrease) (GAAP), the most comparable GAAP measure:



	Three months ended June 30, 2026
	Percentage change versus the year-ago period
	Health and Wellness	Household	Lifestyle	International	Total Company (1)
Net sales growth / (decrease) (GAAP)	16%	(18)%	(17)%	4%	(2)%
Add: Foreign Exchange	—	—	—	(3)	(1)
Add/(Subtract): Divestitures/Acquisitions (2)	(28)	—	—	—	(10)
Organic sales growth / (decrease) (non-GAAP)	(12)%	(18)%	(17)%	1%	(13)%


	Twelve months ended June 30, 2026
	Percentage change versus the year-ago period
	Health and Wellness	Household	Lifestyle	International	Total Company (1)
Net sales growth / (decrease) (GAAP)	—%	(11)%	(14)%	5%	(5)%
Add: Foreign Exchange	—	—	—	(3)	—
Add/(Subtract): Divestitures/Acquisitions (2)	(8)	—	—	—	(3)
Organic sales growth / (decrease) (non-GAAP)	(8)%	(11)%	(14)%	2%	(8)%

(1)Total Company includes Corporate and Other. Corporate and Other includes the results of the Better Health VMS business through the date of divestiture.

Supplemental Unaudited Condensed Information – Gross Margin Drivers

The table below provides details on the drivers of gross margin change versus the year-ago period.


Driver	Gross Margin Change vs. Prior Year (basis points)
	FY25					FY26
	Q1	Q2	Q3	Q4	FY	Q1	Q2	Q3	Q4	FY
Cost Savings	+240	+170	+170	+160	+190	+140	+170	+170	+170	+160
Price Changes	+20	+10	+10	+10	+10	+20	+60	+60	+50	+50
Market Movement (commodities)	+20	-20	-40	-50	-20	-30	0	-50	-120	-50
Manufacturing & Logistics	-10	-30	+40	-170	-40	-180	-240	-210	-90	-170
All other (1) (2) (3) (4) (5)	+470	-100	+60	+50	+80	-360	-50	-110	-530	-280
Change vs prior year	+740	+30	+240	0	+220	-410	-60	-140	-520	-290

Gross Margin (%)	45.8%	43.8%	44.6%	46.5%	45.2%	41.7%	43.2%	43.2%	41.3%	42.3%

(1)In Q1 of fiscal year 2025, "All other" includes the positive impact from higher shipment volumes.

(2)In Q2 of fiscal year 2025, "All other" includes the negative impact from lower shipment volumes.

(3)In Q1 of fiscal year 2026, "All other" includes the negative impact from lower shipment volumes.

(4)In Q3 of fiscal year 2026, "All other" includes the negative impact from mix and assortment.

(5)In Q4 of fiscal year 2026, "All other" includes the negative impact from lower shipment volumes and the negative impact of the inventory step-up of the GOJO acquisition.

Supplemental Unaudited Condensed Information – Cash Flow

For the quarter ended June 30, 2026

Capital expenditures for the fourth quarter were $86 million versus $75 million in the year-ago quarter (Fiscal year 2026 = $207 million).

Depreciation and amortization expense for the fourth quarter was $78 million versus $57 million in the year-ago quarter (Fiscal year 2026 = $247 million).

Net cash provided by operations in the fourth quarter was $330 million, or 16.9% of net sales (Fiscal year 2026 = $612 million, or 9.1% of net sales).

Supplemental Unaudited Condensed Information – Adjusted Free Cash Flow

Fiscal Year Adjusted Free Cash Flow Reconciliation

Dollars in Millions and percentages based on rounded numbers


	Fiscal year 2026	Fiscal year 2025
Net cash provided by operations – GAAP	$612	$981
Less: Capital expenditures	(207)	(220)
Add: Venture agreement termination payment (2)	476	—
Adjusted Free cash flow – non-GAAP (1)	$881	$761
Free cash flow as a percentage of net sales – non-GAAP (1)	13.1%	10.7%
Net sales	$6,720	$7,104

(1)In accordance with the SEC's Regulation G, this schedule provides the definition of certain non-GAAP measures and the reconciliation to the most closely related GAAP measure. Management uses free cash flow and free cash flow as a percentage of net sales to help assess the cash generation ability of the business and funds available for investing activities, such as acquisitions, investing in the business to drive growth and financing activities, including debt payments, dividend payments and stock repurchases. Adjusted free cash flow does not represent cash available only for discretionary expenditures since the Company has mandatory debt service requirements and other contractual and non-discretionary expenditures. In addition, free cash flow may not be the same as similar measures provided by other companies due to potential differences in methods of calculation and items being excluded. These non-GAAP financial measures should not be considered in isolation or as a substitute for the comparable GAAP measures and should be read in connection with the company’s consolidated financial statements presented in accordance with GAAP.

(2)During the third quarter of fiscal year 2026, the Company completed the purchase of The Procter & Gamble Company’s (P&G) interest in the Company’s Glad® bags and wraps business. Management believes adjusting free cash flow to exclude this one‑time payment provides useful information for period‑over‑period comparability and enables investors to better evaluate the Company’s underlying operating performance, consistent with how management assesses operating results.

Supplemental Unaudited Reconciliation of Earnings Before Income Taxes to EBIT (1)(3) and Adjusted EBIT (2)(3)

Dollars in millions and percentages based on rounded numbers


	FY 2025		FY 2026

		Q1	Q2	Q3	Q4	FY	Q1	Q2	Q3	Q4	FY
		9/30/24	12/31/24	3/31/25	6/30/25	6/30/25	9/30/25	12/31/25	3/31/26	6/30/26	6/30/26
Earnings (losses) before income taxes		$177	$237	$254	$410	$1,078	$107	$215	$256	$213	$791
Interest income		(3)	(2)	(2)	(2)	(9)	(2)	(1)	(4)	(1)	(8)
Interest expense		21	22	23	22	88	23	25	27	55	130
EBIT (1)(3)		$195	$257	$275	$430	$1,157	$128	$239	$279	$267	$913
EBIT margin (1)(3)		11.1%	15.2%	16.5%	21.6%	16.3%	9.0%	14.3%	16.7%	13.7%	13.6%
Loss on divestiture(4)		118	—	—	—	118	—	—	—	—	—
Acquisition and integration costs (5)		—	—	—	—	—	—	—	7	51	58
Cyberattack costs, net of insurance recoveries (6)		(10)	(25)	(35)	—	(70)	—	—	—	—	—
Digital capabilities and productivity enhancements investment (7)		29	26	26	30	111	32	17	10	—	59
Adjusted EBIT – non-GAAP (2)(3)		$332	$258	$266	$460	$1,316	$160	$256	$296	$318	$1,030
Adjusted EBIT margin (2)(3)		18.8%	15.3%	15.9%	23.1%	18.5%	11.2%	15.3%	17.7%	16.3%	15.3%
Net sales		$1,762	$1,686	$1,668	$1,988	$7,104	$1,429	$1,673	$1,670	$1,948	$6,720

(1)EBIT (a non-GAAP measure) represents earnings (losses) before income taxes (a GAAP measure), excluding interest income and interest expense, as reported above. EBIT margin is the ratio of EBIT to net sales.

(2)Adjusted EBIT (a non-GAAP measure) represents earnings (losses) before income taxes (a GAAP measure), excluding interest income, interest expense and other significant items that are nonrecurring or unusual (such as the incremental costs and insurance recoveries related to the August 2023 cyberattack, asset impairments, charges related to the digital capabilities and productivity enhancements investment, transaction and integration costs related to acquisitions, significant losses related to divestitures and other nonrecurring or unusual items as reported above). Adjusted EBIT margin is the ratio of adjusted EBIT to net sales. Refer to the Non-GAAP Financial Information within the earnings release for further discussion on the adjustments presented.

(3)In accordance with the SEC's Regulation G, this schedule provides the definition of certain non-GAAP measures and the reconciliation to the most closely related GAAP measure. Management believes the presentation of EBIT, EBIT margin, adjusted EBIT and adjusted EBIT margin provides useful additional information to investors about trends in the company's operations and is useful for comparability of performance over time. These non-GAAP financial measures should not be considered in isolation or as a substitute for the comparable GAAP measures. In addition, these non-GAAP financial measures may not be the same as similar measures provided by other companies due to potential differences in methods of calculation and items being excluded. They should be read in connection with the company’s consolidated financial statements presented in accordance with GAAP.

(4)Represents the loss related to the divestiture of the Better Health VMS businesses.

(5)Represents the expenses related to the company’s acquisition and integration of GOJO.

(6)Reflects insurance recoveries related to the cyberattack.

(7)Reflects the operating expenses incurred by the company related to its digital capabilities and productivity enhancements investment. The majority of these expenses relate to external consulting fees. The remaining expenses relate to internal IT project management and supporting personnel costs and other costs.

Supplemental Unaudited Reconciliation of Non-GAAP Measures (1)(2)

(Dollars in millions except per share data)


Reconciliation of Non-GAAP Measures
	Three months ended June 30, 2026
	As Reported GAAP			Acquisition and integration costs (3)		Adjusted (non-GAAP) (1)(2)
Cost of products sold	$	1,144		$	(30)	$	1,114
Gross profit	804			30		834
Gross margin	41.3		%			42.8		%

Selling and administrative expenses	298			(21)		277
Percent of net sales	15.3		%			14.2		%

Other (income) expense, net	(10)			—		(10)

Net earnings attributable to Clorox	163			39		202

Diluted net earnings per share	$	1.34		$	0.32	$	1.66


Reconciliation of Non-GAAP Measures
	Twelve months ended June 30, 2026
	As Reported GAAP			Acquisition and integration costs (3)		Digital capabilities and productivity enhancements investment (4)		Adjusted (non-GAAP) (1)(2)
Cost of products sold	$	3,876		$	(31)	$	—	$	3,845
Gross profit	2,844			31		—		2,875
Gross margin	42.3		%					42.8		%

Selling and administrative expenses	1,066			(27)		(59)		980
Percent of net sales	15.9		%					14.6		%

Other (income) expense, net	(8)			—		—		(8)

Net earnings attributable to Clorox	587			44		45		676

Diluted net earnings per share	$	4.81		$	0.36	$	0.36	$	5.53

(1)Adjusted Cost of Products Sold, Adjusted Gross Profit, Adjusted Gross Margin, Adjusted Selling and Administrative expenses, Adjusted Other Income (Expense), Adjusted Net Earnings Attributable to Clorox, and Adjusted Diluted Net Earnings Per Share are calculated in accordance with GAAP, that excludes or has otherwise been adjusted for significant items that are nonrecurring or unusual that are not indicative of the Company’s underlying operations. Non-GAAP measures may not be the same as similar measures provided by other companies due to potential differences in methods of calculation or differences in which items are incorporated into these adjustments.

(2)The Non-GAAP measures listed above are supplemental information that management uses to help evaluate the company's historical and prospective financial performance on a consistent basis over time. Management believes that by adjusting for certain items affecting comparability of performance over time investors and management are able to gain additional insight into the company's underlying operating performance on a consistent basis over time.

(3)Represents the expenses related to the company’s acquisition and integration of GOJO.

(4)Reflects the operating expenses incurred by the company related to its digital capabilities and productivity enhancements investment. The majority of these expenses relate to external consulting fees. The remaining expenses relate to internal IT project management and supporting personnel costs and other costs.


Adjusted Diluted Earnings Per Share (EPS)
(Dollars in millions except per share data)

		Diluted earnings per share
		Three months ended
		6/30/2026		6/30/2025		% Change
	As reported (GAAP)	$	1.34	$	2.68	(50)	%

	Acquisition and integration costs (2)	0.32		—

	Digital capabilities and productivity enhancements investment (4)	—		0.19
	As adjusted (Non-GAAP) (5)(6)	$	1.66	$	2.87	(42)	%

		Diluted earnings per share
		Twelve months ended
		6/30/2026		6/30/2025		% Change
	As reported (GAAP)	$	4.81	$	6.52	(26)	%
	Loss on divestiture (1)	—		0.94
	Acquisition and integration costs (2)	0.36		—
	Cyberattack costs, net of insurance recoveries (3)	—		(0.42)
	Digital capabilities and productivity enhancements investment (4)	0.36		0.68
	As adjusted (Non-GAAP) (5)(6)	$	5.53	$	7.72	(28)	%

(1)During the twelve months ended June 30, 2026, the company incurred an after tax charge of $118 related to the divestiture of the Better Health VMS business.

(2)During the three and twelve months ended June 30, 2026, the company incurred approximately $51 ($39 after tax) and $58 ($44 after tax), of costs related to the GOJO acquisition.

(3)During the twelve months ended June 30, 2025, the company recognized $70 ($53 after tax) of insurance recoveries related to the August 2023 cyberattack.

(4)During the three and twelve months ended June 30, 2026, the company incurred $0 and approximately $59 ($45 after tax), respectively, and during the three and twelve months ended June 30, 2025, the company incurred approximately $30 ($23 after tax), and $111 ($85 after tax), respectively, of operating expenses related to its digital capabilities and productivity enhancements investment.

(5)Adjusted EPS is defined as diluted earnings (losses) per share that excludes or has otherwise been adjusted for significant items that are nonrecurring or unusual. The income tax effect on non-GAAP items is calculated based upon the tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment.

(6)Adjusted EPS is supplemental information that management uses to help evaluate the company's historical and prospective financial performance on a consistent basis over time. Management believes that by adjusting for certain items affecting comparability of performance over time, such as the incremental costs and insurance recoveries related to the August 2023 cyberattack, asset impairments, charges related to the digital capabilities and productivity enhancements investment, transaction and integration costs related to acquisitions, significant losses related to divestitures and other nonrecurring or unusual items, investors and management are able to gain additional insight into the company's underlying operating performance on a consistent basis over time. However, adjusted EPS may not be the same as similar measures provided by other companies due to potential differences in methods of calculation or differences in which items are incorporated into these adjustments. Refer to the Non-GAAP Financial Information within the earnings release for further discussion on the adjustments presented.


	Full year 2027 outlook
	Estimated range
	Diluted earnings per share
	Low		High
As estimated (GAAP)	$	5.41	$	5.71
Acquisition and integration costs (7)	0.29		0.29

As adjusted (Non-GAAP) (5)(6)	$	5.70	$	6.00

(7)In fiscal year 2027, the company expects to incur approximately $46 ($35 after tax) of costs related to the GOJO acquisition.

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

5 documents